CN-122005760-A - Application of IL-24 recombinant protein in preparation of medicines for treating allergic rhinitis

Abstract

The invention relates to the field of biological medicine, in particular to application of IL-24 recombinant protein in preparing a medicine for treating allergic rhinitis. The invention utilizes the IL-24 recombinant protein, can reduce the local type 2 inflammation level of nasal mucosa, reduce the expression of inflammatory factors such as IL-4, IL-5, IL-13 and the like and chemokines CCL24 and CCL26, and lighten the infiltration of local inflammatory cells of the nasal mucosa, thereby relieving the symptoms of patients such as sneeze, nose grabbing and the like. At the same time, a new treatment option is provided for patients who are not effective in hormone resistance or desensitization treatment.

Inventors

• LIU ZHENG
• LI JINGXIAN
• YAO YIN
• WANG ZHICHAO
• XIANG WENXUAN

Assignees

• 华中科技大学同济医学院附属同济医院

Dates

Publication Date

20260512

Application Date

20260115

Claims (9)

1. Application of IL-24 recombinant protein in preparing medicine for treating allergic rhinitis.
2. 2. The use according to claim 1, wherein the medicament is a medicament for reducing the level of local type 2 inflammation of the nasal mucosa.
3. 3. The use according to claim 2, wherein the medicament is a medicament for reducing the expression level of IL-4, IL-5, IL-13 inflammatory factors.
4. 4. The use of claim 2, wherein the agent is an agent that reduces the expression levels of CCL24 and CCL26 chemokines.
5. 5. The use according to claim 1, wherein the medicament is a medicament for reducing infiltration of local inflammatory cells of the nasal mucosa.
6. 6. The use according to claim 5, wherein the medicament is a medicament for reducing local total inflammatory cell infiltration of nasal mucosa.
7. 7. The use according to claim 5, wherein the medicament is a medicament for reducing local eosinophil infiltration of nasal mucosa.
8. 8. The use of claim 1, wherein the mode of administration of the medicament comprises at least one of oral administration, intravenous administration, and intraperitoneal administration.
9. 9. The use according to claim 1, wherein the medicament is in any pharmaceutically acceptable dosage form, including at least one of tablets, capsules, injections, granules, suspensions and solutions.

Description

Application of IL-24 recombinant protein in preparation of medicines for treating allergic rhinitis Technical Field The invention relates to the technical field of biological medicines, in particular to an application of IL-24 recombinant protein in preparing a medicine for treating allergic rhinitis. Background Allergic rhinitis (ALLERGY RHINITIS, AR) is a type I hypersensitivity mediated by immunoglobulin E (IgE) following nasal mucosal contact with allergens, one of the most common upper airway diseases worldwide. AR not only severely affects the quality of life of the patient but also will cause tremendous consumption of social medical resources. In addition, AR also severely affects the occurrence, progression and prognosis of lower respiratory tract disease. AR was found to be an independent risk factor for asthma and about 40% of AR patients could have asthma combined, but AR was severely underestimated clinically and the therapeutic effect was far from satisfactory. Moreover, even according to the standard drug treatment scheme recommended by the guidelines of allergic rhinitis and its effect on asthma (ALLERGIC RHINITIS AND ITS IMPACT on asthma, ARIA), nearly 20% of patients still have symptoms which are not effectively improved, suggesting that the pathogenesis of AR is further clarified, searching for new AR treatment targets, and having important clinical significance and realistic necessity for improving AR curative effect. This importance and necessity is also demonstrated by the development of AR biotherapy. Early studies demonstrated that type I hypersensitivity mediated by IgE is one of the pathogenesis of AR. In recent years, the anti-IgE drug amazumab is successfully developed based on the mechanism, so that the symptoms of AR patients which are difficult to control in conventional treatment can be effectively relieved, and the encouraging clinical treatment prospect of biological treatment drugs is revealed. However, this drug can only bind to free IgE in the body and cannot fundamentally control the occurrence and development of AR. Therefore, there is an urgent need to further develop and elucidate the pathogenesis of AR, and provide new targets for clinical treatment, so as to improve the therapeutic level of AR, which is a hot spot problem that needs to be solved in the nasal science community of all countries in the world. Disclosure of Invention Therefore, the invention aims to provide an application of the IL-24 recombinant protein in preparing medicines for treating allergic rhinitis, and the IL-24 recombinant protein can weaken or even eliminate local inflammation of AR so as to achieve better AR treatment effect, reduce side effects of the existing treatment mode and provide possibility for AR treatment. In order to achieve the above purpose, the technical scheme adopted by the invention is as follows: the invention provides an application of IL-24 recombinant protein in preparing a medicament for treating allergic rhinitis. As a further optimization of the invention, the medicament is a medicament for reducing the local type 2 inflammation level of nasal mucosa. As a further optimization scheme of the invention, the medicine is a medicine for reducing the expression level of IL-4, IL-5 and IL-13 inflammatory factors. As a further optimization of the invention, the drug is a drug that reduces the expression level of CCL24 and CCL26 chemokines. As a further optimization scheme of the invention, the medicine is used for reducing infiltration of local inflammatory cells of nasal mucosa. As a further optimization scheme of the invention, the medicine is used for relieving local total inflammatory cell infiltration of nasal mucosa. As a further optimization scheme of the invention, the medicine is a medicine for relieving local eosinophil infiltration of nasal mucosa. As a further preferred embodiment of the present invention, the administration mode of the drug includes at least one of oral administration, intravenous administration and intraperitoneal administration. As a further optimized scheme of the invention, the medicine is in any pharmaceutically acceptable dosage form, including at least one of tablets, capsules, injections, granules, suspensions and solutions. The invention develops around the application of IL-24 recombinant protein in preparing a medicament for treating allergic rhinitis, and shows various remarkable technical effects: The IL-24 recombinant protein can reduce the local type 2 inflammatory level of nasal mucosa, obviously reduce the expression level of inflammatory factors such as IL-4, IL-5, IL-13 and the like and chemokines of CCL24 and CCL26, and also can reduce the local inflammatory cell infiltration of the nasal mucosa, including total inflammatory cell infiltration and eosinophil infiltration, and inhibit the inflammatory reaction of allergic rhinitis from multiple aspects. Experiments on HDM-induced mouse AR model show that after IL-24 recombinan